RxDoctor Payments Data

Timothy Carrabine, MD

Internal Medicine · Uniontown, OHNPI 1215015870

Payments from drug & device makers

$109,298in general payments, 2019–2025

Across 835 payments — averaging $130.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$42K
  • Sanofi$37K
  • Bristol Myers Squibb$17K
  • Genentech USA, Inc.$8K
  • Novartis$1K
  • EMD Serono, Inc.$1K
  • plus $3K from 23 others

What the payments were for

  • Consulting fees$23,81722%
  • Speaking & faculty fees$64,73759%
  • Travel & lodging$4,9855%
  • Food & beverage$15,44114%
  • Education$3180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$109,298 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$2,274,677
Medicare patients
88
Services billed
68,151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab120$1,104,253
CopaxoneGlatiramer Acetate104$608,903
Avonex Pen (4 Pack)Interferon Beta-1a52$462,012
AubagioTeriflunomide25$233,742
Teriflunomide83$220,382
Glatiramer Acetate91$214,715
VumerityDiroximel Fumarate26$212,518
RebifInterferon Beta-1a/Albumin13$135,522
GlatopaGlatiramer Acetate35$90,461
Dimethyl Fumarate35$43,013
Dalfampridine ErDalfampridine51$27,712
MyrbetriqMirabegron16$12,377
LinzessLinaclotide22$12,008
FingolimodFingolimod Hcl18$9,105
Baclofen404$7,695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$19$608,903104 claims
SanofiAubagio$37,083$233,74225 claims
BiogenVumerity$41,892$212,51826 claims
EMD Serono, Inc.Rebif$1,107$135,52213 claims
AbbVieLinzess$41$12,00822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Uniontown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →